HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 4807人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308549, encodeId=3d661308549a5, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet：HER2阳性早期乳腺癌术后辅助治疗：12个月与6个月的战争, objectType=article, longId=179496, objectId=1dea1e949680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dea1e949680, replyNumber=0, likeNumber=92, createdTime=2019-09-17, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dea1e949680, moduleTitle=Lancet：HER2阳性早期乳腺癌术后辅助治疗：12个月与6个月的战争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dea1e949680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308548, encodeId=b43213085489f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=闫敏教授：从证据到实践，吡咯替尼为HER2阳性晚期乳腺癌治疗带来哪些改变, objectType=article, longId=179296, objectId=961a1e92963d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961a1e92963d, replyNumber=0, likeNumber=98, createdTime=2019-09-13, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961a1e92963d, moduleTitle=闫敏教授：从证据到实践，吡咯替尼为HER2阳性晚期乳腺癌治疗带来哪些改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961a1e92963d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308547, encodeId=5d94130854e55, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=新辅助抗HER2治疗，给HER2阳性早期乳腺癌创造手术机会, objectType=article, longId=178539, objectId=bff51e853922, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bff51e853922, replyNumber=0, likeNumber=74, createdTime=2019-09-03, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bff51e853922, moduleTitle=新辅助抗HER2治疗，给HER2阳性早期乳腺癌创造手术机会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bff51e853922)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308546, encodeId=0600130854601, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：HER2阳性转移性乳腺癌研究进展, objectType=article, longId=178332, objectId=005e1e833230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005e1e833230, replyNumber=0, likeNumber=0, createdTime=2019-08-30, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005e1e833230, moduleTitle=JCO：HER2阳性转移性乳腺癌研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005e1e833230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308545, encodeId=9ffa1308545e4, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=新辅助用“曲帕”双靶，给年轻HER2阳性乳腺癌患者带来生存获益, objectType=article, longId=177137, objectId=eb151e713790, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb151e713790, replyNumber=0, likeNumber=85, createdTime=2019-08-09, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb151e713790, moduleTitle=新辅助用“曲帕”双靶，给年轻HER2阳性乳腺癌患者带来生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb151e713790)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308544, encodeId=e2a413085445b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=合理选择，规范抗HER——抗HER2药物给HER2阳性乳腺癌带来生存希望, objectType=article, longId=175839, objectId=45771e5839f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45771e5839f1, replyNumber=0, likeNumber=95, createdTime=2019-07-22, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45771e5839f1, moduleTitle=合理选择，规范抗HER——抗HER2药物给HER2阳性乳腺癌带来生存希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45771e5839f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308543, encodeId=8ac5130854364, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗, objectType=article, longId=175669, objectId=17911e5669f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17911e5669f5, replyNumber=0, likeNumber=85, createdTime=2019-07-19, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17911e5669f5, moduleTitle=Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17911e5669f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308542, encodeId=d0a8130854239, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet：早期HER2阳性乳腺癌患者可采用6个月曲妥珠单抗治疗方案, objectType=article, longId=174435, objectId=e0b31e443588, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0b31e443588, replyNumber=0, likeNumber=72, createdTime=2019-06-30, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0b31e443588, moduleTitle=Lancet：早期HER2阳性乳腺癌患者可采用6个月曲妥珠单抗治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0b31e443588)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308541, encodeId=9e281308541a6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新, objectType=article, longId=168877, objectId=2c901688e7bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c901688e7bc, replyNumber=0, likeNumber=67, createdTime=2019-06-22, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c901688e7bc, moduleTitle=ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c901688e7bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308540, encodeId=b0141308540df, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌的升阶治疗和降阶治疗的热点, objectType=article, longId=168462, objectId=c35916846256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c35916846256, replyNumber=0, likeNumber=78, createdTime=2019-06-17, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c35916846256, moduleTitle=HER2阳性乳腺癌的升阶治疗和降阶治疗的热点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c35916846256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308539, encodeId=6ccb130853914, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=SOPHIA初步结果开辟HER2阳性晚期乳腺癌治疗新途径, objectType=article, longId=168401, objectId=633a16840184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=633a16840184, replyNumber=0, likeNumber=61, createdTime=2019-06-15, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=633a16840184, moduleTitle=SOPHIA初步结果开辟HER2阳性晚期乳腺癌治疗新途径, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=633a16840184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308538, encodeId=dff613085380b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=以抗HER2为中心，为晚期HER2阳性乳腺癌赢得20个月宝贵时间, objectType=article, longId=168157, objectId=66dc16815e6f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66dc16815e6f, replyNumber=0, likeNumber=65, createdTime=2019-06-13, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66dc16815e6f, moduleTitle=以抗HER2为中心，为晚期HER2阳性乳腺癌赢得20个月宝贵时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66dc16815e6f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308537, encodeId=546e130853ea2, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=殷文瑾教授：复发/难治性HER2阳性转移性乳腺癌患者的新期待, objectType=article, longId=167882, objectId=cd6516e8827a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd6516e8827a, replyNumber=0, likeNumber=60, createdTime=2019-06-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd6516e8827a, moduleTitle=殷文瑾教授：复发/难治性HER2阳性转移性乳腺癌患者的新期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd6516e8827a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308536, encodeId=72c01308536b6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, objectType=article, longId=167604, objectId=9de016e60451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9de016e60451, replyNumber=0, likeNumber=62, createdTime=2019-06-05, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9de016e60451, moduleTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9de016e60451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, objectType=article, longId=166718, objectId=55b4166e1844, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55b4166e1844, replyNumber=0, likeNumber=81, createdTime=2019-05-25, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55b4166e1844, moduleTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55b4166e1844)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308534, encodeId=6a0c130853425, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌治疗的新近进展与展望, objectType=article, longId=166395, objectId=938b1663956d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=938b1663956d, replyNumber=0, likeNumber=75, createdTime=2019-05-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=938b1663956d, moduleTitle=HER2阳性乳腺癌治疗的新近进展与展望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=938b1663956d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308533, encodeId=961b130853325, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2指南者说丨张清媛教授：从《2019 CSCO乳腺癌诊疗指南》更新要点看HER2阳性晚期乳腺癌治疗格局的改变, objectType=article, longId=165416, objectId=5e681654165a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e681654165a, replyNumber=0, likeNumber=64, createdTime=2019-05-07, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e681654165a, moduleTitle=HER2指南者说丨张清媛教授：从《2019 CSCO乳腺癌诊疗指南》更新要点看HER2阳性晚期乳腺癌治疗格局的改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e681654165a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308532, encodeId=773c1308532cd, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性, objectType=article, longId=165380, objectId=4e2c165380ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c165380ae, replyNumber=0, likeNumber=77, createdTime=2019-05-06, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c165380ae, moduleTitle=Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2c165380ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308531, encodeId=4c491308531a0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：帕妥珠单抗联合曲妥珠单抗治疗HER2阳性结肠癌, objectType=article, longId=162238, objectId=18f71622382c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18f71622382c, replyNumber=0, likeNumber=105, createdTime=2019-03-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18f71622382c, moduleTitle=Lancet Oncol：帕妥珠单抗联合曲妥珠单抗治疗HER2阳性结肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18f71622382c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308530, encodeId=fecc130853000, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JAMA Oncol：可手术的HER2阳性乳腺癌：序贯化疗vs同期化疗, objectType=article, longId=161417, objectId=c42516141ef1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c42516141ef1, replyNumber=0, likeNumber=66, createdTime=2019-03-02, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c42516141ef1, moduleTitle=JAMA Oncol：可手术的HER2阳性乳腺癌：序贯化疗vs同期化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c42516141ef1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet：HER2阳性早期乳腺癌术后辅助治疗：12个月与6个月的战争

2019-09-17

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

闫敏教授：从证据到实践，吡咯替尼为HER2阳性晚期乳腺癌治疗带来哪些改变

2019-09-13

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

新辅助抗HER2治疗，给HER2阳性早期乳腺癌创造手术机会

2019-09-03

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：HER2阳性转移性乳腺癌研究进展

2019-08-30

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

新辅助用“曲帕”双靶，给年轻HER2阳性乳腺癌患者带来生存获益

2019-08-09

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

合理选择，规范抗HER——抗HER2药物给HER2阳性乳腺癌带来生存希望

2019-07-22

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗

2019-07-19

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet：早期HER2阳性乳腺癌患者可采用6个月曲妥珠单抗治疗方案

2019-06-30

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新

2019-06-22

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌的升阶治疗和降阶治疗的热点

2019-06-17

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

SOPHIA初步结果开辟HER2阳性晚期乳腺癌治疗新途径

2019-06-15

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

以抗HER2为中心，为晚期HER2阳性乳腺癌赢得20个月宝贵时间

2019-06-13

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

殷文瑾教授：复发/难治性HER2阳性转移性乳腺癌患者的新期待

2019-06-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）

2019-06-05

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌

2019-05-25

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌治疗的新近进展与展望

2019-05-21

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2指南者说丨张清媛教授：从《2019 CSCO乳腺癌诊疗指南》更新要点看HER2阳性晚期乳腺癌治疗格局的改变

2019-05-07

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性

2019-05-06

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：帕妥珠单抗联合曲妥珠单抗治疗HER2阳性结肠癌

2019-03-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JAMA Oncol：可手术的HER2阳性乳腺癌：序贯化疗vs同期化疗

2019-03-02

科室
- - 订阅+
  - 更多科室
工具
服务